Gc Biopharma
Gc Biopharma, officially known as Green Cross Biopharma, is a leading biopharmaceutical company headquartered in South Korea (KR). Established in 1967, the company has made significant strides in the biopharmaceutical industry, focusing on the development and production of innovative therapies, particularly in the fields of immunology and infectious diseases. With a strong presence in Asia and expanding operations globally, Gc Biopharma is renowned for its core products, including plasma-derived therapies and vaccines. These offerings are distinguished by their high quality and efficacy, positioning the company as a trusted provider in the healthcare sector. Notable achievements include its commitment to research and development, which has propelled Gc Biopharma to a prominent market position, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Gc Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gc Biopharma's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gc Biopharma's reported carbon emissions
In 2023, Gc Biopharma reported total carbon emissions of approximately 40,000,000 kg CO2e, comprising 10,804,000 kg CO2e from Scope 1, 54,001,000 kg CO2e from Scope 2, and 16,542,000 kg CO2e from Scope 3 emissions. This data reflects a commitment to transparency in their environmental impact, inherited from their parent company, GC Biopharma Corp. Comparatively, in 2022, the company recorded total emissions of about 41,000,000 kg CO2e, with Scope 1 emissions at 12,374,000 kg CO2e, Scope 2 at 54,480,000 kg CO2e, and Scope 3 at 17,704,000 kg CO2e. This indicates a slight reduction in total emissions year-on-year. Despite these figures, Gc Biopharma has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction strategies suggests a need for further commitment to climate action within the biopharmaceutical sector. Overall, Gc Biopharma's emissions data highlights the importance of ongoing monitoring and the potential for future climate commitments to align with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 14,362,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 53,804,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 7,480,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gc Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
